Rhinitis Medicamentosa Follow-up

Updated: Jan 02, 2018
  • Author: Mark S Dykewicz, MD; Chief Editor: Michael A Kaliner, MD  more...
  • Print
Follow-up

Further Outpatient Care

Short-term follow-up may be needed to assess whether additional medical intervention is required.

Next:

Deterrence/Prevention

Patients should be instructed to avoid topical vasoconstrictors in the future. Studies showed that those with a history of rhinitis medicamentosa who successfully stop using the offending medication have a rapid onset of rebound congestion upon repeat use of topical vasoconstrictor medication, even if used for only a few days. [19]  

Placebo-controlled studies of perennial and seasonal allergic rhinitis demonstrate that concurrent administration of intranasal corticosteroids and intranasal decongestants provide additional benefit in relief of nasal congestion. When an intranasal decongestant was given along with the intranasal steroid once a day for up to 4 weeks, the development of rhinitis medicamentosa did not occur. [23, 24]  One study reported that rebound congestion from the intranasal decongestant oxymetazoline was reversed by intranasal corticosteroid use. [25]

Further long-term studies are needed to determine how effective concomitant administration of intranasal decongestant and intranasal corticosteroid is as a strategy to avoid development of rhinitis medicamentosa.

Previous